Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
DACH1 as a multifaceted and potentially druggable susceptibility factor for kidney disease
Sandra Merscher, Christian Faul
Sandra Merscher, Christian Faul
Published May 17, 2021
Citation Information: J Clin Invest. 2021;131(10):e149043. https://doi.org/10.1172/JCI149043.
View: Text | PDF
Commentary Article has an altmetric score of 3

DACH1 as a multifaceted and potentially druggable susceptibility factor for kidney disease

  • Text
  • PDF
Abstract

Kidney diseases affect more than 15% of adults in the US, yet drug development in the kidney field, when compared with that for other common diseases, has been lagging behind. Modifiers that increase the susceptibility to injury and contribute to the pathogenesis and progression of kidney disease include genetic and environmental factors and epigenetic mechanisms. In this issue of the JCI, Cao et al. and Doke et al. independently report the identification of a susceptibility factor called Dachshund homolog 1 (DACH1). Both groups identify an association of reduced DACH1 expression with kidney disease, using different screening approaches, studying different types of human kidney diseases, and using different experimental models, making the fact that both stumbled over the same protein very compelling. Combined, these studies highlight DACH1 as a key safeguard in the kidney, granting various cell types proper function by modulating several molecular pathways.

Authors

Sandra Merscher, Christian Faul

×

Figure 1

Decreased podocyte and tubular DACH1 expression is a susceptibility factor for various kidney diseases.

Options: View larger image (or click on image) Download as PowerPoint
Decreased podocyte and tubular DACH1 expression is a susceptibility fact...
In podocytes (left), DACH1 is a safeguard in the nucleus that limits histone H3 lysine 4 trimethylation (H3K4Me3), thereby preventing transcriptional activation of several genes. DACH1 interacts with pax transactivation-domain interacting protein (PTIP), an essential component of the H3K4Me3 complex, which results in reduced promoter methylation and transcriptional repression. Modifiers, which can be of genetic, epigenetic, or environmental origin, can lead to reduced DACH1 expression and to transcriptional derepression of target genes, making podocytes more susceptible to a second insult. A second insult, such as high glucose levels, may ultimately cause podocyte injury and albuminuria. In tubular cells (right), DACH1 acts as a transcriptional suppressor of cell-cycle genes and of proinflammatory cytokines. Modifiers leading to reduced tubular DACH1 expression and to transcriptional derepression of target genes make the tubular cells more susceptible to a second insult, such as folic acid–induced kidney injury or hyperglycemia, ultimately causing tubular cell proliferation or injury and eventually renal inflammation and fibrosis. For both cell types, modifiers and mechanisms that induce the reduction of DACH1 expression are currently unknown.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Posted by 5 X users
On 1 Facebook pages
10 readers on Mendeley
See more details